What is NeuroComp Systems?
NeuroComp Systems, Inc. is a research corporation dedicated to advancing treatments for debilitating central nervous system disorders, including Alzheimer's disease and schizophrenia. For over 25 years, the company has leveraged its expertise in hardware-software technology to create pioneering solutions. Their flagship products, the CMINDS neurocognitive assessment system and its remote counterpart, CMINDS-R, offer comprehensive evaluations crucial for healthcare providers and researchers. Beyond product development, NeuroComp Systems also provides electronic innovation support and engages in collaborative projects, such as the Cerebral Palsy Risk Identification System, underscoring their commitment to neurocognitive health.
How much funding has NeuroComp Systems raised?
NeuroComp Systems has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
What's next for NeuroComp Systems?
With the recent substantial expansion capital, NeuroComp Systems is poised for significant growth and scaling. The company's strategic focus on developing innovative technology for CNS disorders, coupled with its established experience and product suite, positions it well for future advancements. This investment will likely fuel further research and development, enhance market penetration for its CMINDS assessment tools, and potentially expand its collaborative efforts in neurocognitive health research. The company's trajectory suggests a strong emphasis on translating technological innovation into tangible improvements for patient care and scientific understanding.
See full NeuroComp Systems company page
